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APC = antigen-presenting cell; DC = dendritic cell; HSV = herpes simplex virus; IFN = interferon; IL = interleukin; LCMV = lymphocytic chori-
omeningitis virus; MHC = major histocompatability complex; MV = measles virus; TNF = tumor necrosis factor; TRAIL = tumor necrosis factor
related apoptosis-inducing ligand.
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Introduction
Many viruses utilize the respiratory tract as an entry point
into the host. They may target specialized cells of the res-
piratory tract for initial replication, leading to disease that
primarily manifests as illnesses of the lung and upper
airways. Alternatively, they may infect mobile elements that
are resident in the respiratory tract, or produce viremia
that can carry the virus to a secondary target organ. The
outcome of these encounters is determined by the early
events that occur in the lung at the interface of the innate
and adaptive immune responses. The DC has primary
responsibility for antigen processing, antigen presentation
and T lymphocyte activation, and thus initiates and shapes
the adaptive immune response. The ways in which DCs
translate messages regarding the lung milieu to T lympho-
cytes dictate the magnitude, kinetics, and composition of
the adaptive immune response, and thereby determine the
characteristics of virus-induced disease.
Dendritic cells as antigen-presenting cells
DCs are derived from myeloid CD34+ progenitors in the
bone marrow, which can differentiate down one of two pre-
cursor pathways (for review see [1]). CD34+ progenitors
may develop into CD14+CD11c+CD1– monocytes, from
which immature DCs can be produced in response to gran-
ulocyte–macrophage colony-stimulating factor and IL-4,
whereas exposure to macrophage colony-stimulating factor
leads to macrophage differentiation. The CD34+ myeloid
progenitors can also differentiate into CD14–CD11c+ pre-
cursors that yield Langerhans cells in response to granulo-
cyte–macrophage colony-stimulating factor, IL-4, and
transforming growth factor-b, or macrophages in response
to macrophage colony-stimulating factor.
Immature DCs are particularly adept in their ability to
capture antigen, and can do so either by macropinocytosis;
by endocytosis through C-type lectin receptors, FcgRI, or
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FcgRII; or by phagocytosis. The process of antigen
capture changes the immature DC both in phenotype and
function, transforming the DC into an antigen-presenting
cell (APC). The maturation of the DC leads to the migra-
tion of the cell from the peripheral tissues into the draining
lymphoid organs. CD40 ligand, as well as tumor necrosis
factor (TNF)-a and IL-1b, activate DCs, and are important
in the conversion of DCs from cells that are primarily
involved in antigen capture into APCs.
The transformation into mature DCs is associated with the
loss of receptors that are involved in endocytosis and
phagocytosis; an increase in the costimulatory molecules
CD40, CD58, CD80, and CD86; a change in morphol-
ogy; and a decreased expression of CD68 and increase in
DC-lysosome-associated membrane protein. DCs exit
nonlymphoid organs through the afferent lymph, and
migrate into the T cell area of lymphoid organs through the
coordinated activity of lipopolysaccharide produced by
pathogens, the local production of TNF-a and IL-1b, and
specific chemokines.
Following antigen uptake and maturation, DCs increase
expression of CCR7. The latter is a receptor for the
chemokines macrophage inflammatory protein-3b and
6Ckine, which are produced by cells in the lymph node T
cell zone, and are responsible for migration of mature
DCs into the paracortical area of lymphoid tissue. When
DCs encounter T lymphocytes, further DC maturation
occurs through CD40 ligand and additional molecules,
causing the release of cytokines such as IL-8, fractalkine,
and macrophage derived chemokines that can attract
lymphocytes. As a result of their maturation process, DCs
efficiently express major histocompatability complex
(MHC) molecules, which contain peptide fragments of
the processed antigen on their cell surface that can be
presented to T lymphocytes in the paracortical area.
When a T lymphocyte has a T cell receptor that is specific
for a particular MHC–antigen fragment complex presented
by a DC, that T lymphocyte becomes activated when
appropriate costimulatory interactions between the DC and
T lymphocyte are present (for review see [1]). These cos-
timulatory signals include the interaction of CD80 or CD86
(also known as B7.1 and B7.2, respectively) that is present
on the DC with CD28 that is present on the T cell. Without
costimulation the T cell receptor–MHC interaction leads to
apoptosis rather than activation. DCs present antigen via
their MHC class II molecules to CD4+ T lymphocytes.
CD4+ T lymphocytes are generally divided into two main
classes – type 1 and type 2 – that are characterized by the
cytokine array produced by the cell. Type 1 cells are impor-
tant in the immune response to intracellular pathogens
such as viruses and mycobacteria, and produce IFN-g, lym-
photoxin, and IL-2. Type 2 cells produce a variety of proin-
flammatory cytokines, such as IL-4, IL-5, IL-9, IL-10 and
IL-13, which are generally important in the development of
the humoral immune response. DCs may have an important
role in determining the profile of cytokines produced by
CD4+ cells. DCs may have an important role in determining
the profile of cytokines produced by CD4+ cells. In
humans, antigen presentation and T-cell activation by the
monocyte-derived CD11c+ DCs secrete IL-12, leading to a
Type 1 cytokine profile. In contrast, CD11c– DCs induce
CD4+ cells to produce type 2 cytokines [1].
Dendritic cells in antiviral immunity
Because DCs have the ability to capture and process
antigen in tissue in the initial stages of a viral infection,
they are particularly suited to prime antiviral immunity.
CD8+ T lymphocytes are also very important in host
immunity to viral infections. CD8+ lymphocytes recognize
eight- or nine-amino-acid peptide epitopes presented in
the context of MHC class I molecules, leading to lysis of
the infected target cell. DCs are particularly effective in
antigen presentation, and costimulation and activation of
CD8+ cytotoxic T lymphocytes. For example, DCs
infected with polyomavirus, but not infected
macrophages, have the capability to prime polyomavirus-
specific CD8+ T lymphocytes in vivo [2,3]. DCs infected
with other viruses (e.g. influenza [4] and lymphocytic
choriomeningitis virus [LCMV] [5]) also induce antigen-
specific CD8+ T lymphocytes.
In a model of influenza A virus infection, mature DCs are
superior to immature DCs in stimulating IFN-g production
from CD8+ effector cells [6]. Additionally, only mature
DCs, and not immature DCs, have the capability to stimu-
late expansion and differentiation of cytotoxic T lympho-
cyte effectors over a one-week period.
Recently, King et al [7] found that IL-4 has a profound
effect on DC antigen presentation of LCMV and the T lym-
phocyte response to viral infection. In this mouse model of
autoimmune diabetes the LCMV nucleoprotein is
expressed in the b-cells of the pancreas, and destruction
of the pancreas can be induced by infecting the mice with
LCMV, thus causing obliteration of the pancreatic islet by
LCMV-specific cytolytic T cells. However, the pancreatic
destruction that follows LCMV infection can be inhibited in
mice that express IL-4 via the human insulin promoter. IL-4
suppresses this virally induced diabetes by blocking the
production of LCMV-nucleoprotein specific cytotoxic T
cells. Further analysis revealed that IL-4 increased the
number of antigen-specific CD8+ cells, but inhibited the
differentiation of cytotoxic precursors by LCMV-pulsed
DCs by increasing B7.2 and decreasing B7.1 expression.
Changes in DC antigen presentation and costimulation
may also explain recent findings from our laboratory that
showed that IL-4 inhibits virus-specific CD8+ cytolytic
activity [8], and shifts the mechanism of lysis from more
perforin mediated to more Fas ligand mediated [9].c
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Effective T cell function is dependent on the maturation of
DCs for optimal antigen presentation via the MHC
complex. Some viral infections, such as influenza, promote
DC maturation after uptake, improving the ability of the
host to kill the virus [10–13]. In contrast, poxviruses have
developed several different mechanisms to evade immune
recognition and elimination. For example, vaccinia inhibits
DC maturation within one day after infection, particularly in
immature DCs, which have a greater propensity for vac-
cinia infection, while mature DCs are more likely to func-
tion as APCs [14]. Immature DCs that are infected with
vaccinia have decreased expression of CD25, CD83,
CD86 and human leukocyte antigen DR (markers of
mature DCs) as compared with noninfected immature
DCs that have also been treated with monocyte-condi-
tioned media, a factor that is known to cause DC matura-
tion [14]. A decrease in CD86 on the DC cell surface
could lead to antigenic tolerance, whereas decreased
human leukocyte antigen DR expression results in
decreased antigen presentation. Vaccinia infection of
mature DCs had a lesser effect on DC function [14]. Vac-
cinia infection of DCs also leads to abortive replication
and induction of DC apoptosis – events that further sup-
press the immune response to vaccinia [14]. In addition,
the poxviruses encode receptor homologs of cytokines
such as IL-1b, TNF-a, IFN-a/b and IFN-g, which are impor-
tant in the host defense against viral infections [15]. IFN-a,
TNF-a, and IL-1b are among the key cytokines that are
involved in the induction of DC maturation [13,16–18].
Measles virus (MV) infection has long been recognized as
producing a significant systemic immunosuppression that
leads to a high mortality rate in undernourished children.
MV mediates immunosuppression at the level of the APC
by a variety of mechanisms. The binding of MV hemagglu-
tinin to its receptor CD46 results in downregulation of
IL-12 [19] and delayed-type hypersensitivity responses
[20]. MV has also been shown to inhibit DC maturation,
and thus the ability of DCs to present antigen to T lympho-
cytes. Ordinarily, the CD40 ligand expressed on activated
T cells induces terminal differentiation of DCs into mature
effector DCs [21,22]. However, the CD40 ligand depen-
dent maturation of DCs is prevented by MV [23]. This has
an added effect on the inhibition of IL-12 production [23].
IL-12 is a critical cytokine in the differentiation of CD4+
type 0 cells to become CD4+ type 1 cells that produce the
antiviral cytokine IFN-g and the potent T cell stimulatory
cytokine IL-2 [24]. MV replication also diminishes CD80
and CD86 expression on DCs, leading to less effective
antigen presentation to T lymphocytes [23]. In addition to
its inhibition of DC maturation, MV also abrogates CD40
ligand dependent CD8+ T cell proliferation [23].
MV infected DCs can also induce T lymphocyte apoptosis,
further impairing the immune response. The mechanism by
which MV causes this effect is through MV induction of TNF
related apoptosis-inducing ligand (TRAIL) mRNA and
protein expression in human monocyte derived DCs [25].
TRAIL is not believed to be cytotoxic to normal cells, but has
been shown to induce apoptosis in several transformed cell
lines [26]. Several lines of evidence suggest that TRAIL is
involved in lymphocyte apoptosis and participates in the
abnormal apoptosis that occurs with infection by immuno-
suppressive viruses such as HIV type 1, particularly
because T lymphocytes from HIV type 1 infected patients
are very susceptible to TRAIL induced cell death [26].
DC function is inhibited by other viruses also. Herpes
simplex virus (HSV) type 1 interferes with antigen presen-
tation and DC cytokine production [27]. The HSV
encoded protein, infected cell peptide 47, has been
shown to bind to the transporter associated with antigen
processing, and thereby interferes with translocation of
processed antigen into the endoplasmic reticulum for
association with MHC class I molecules [28,29]. In addi-
tion, HSV-1 infection of mature DCs alters their function
and phenotype, resulting in impaired T lymphocyte stimula-
tory capacity. HSV-1 infection specifically leads to degra-
dation of CD83, a cell surface molecule of unknown
function that has increased expression during DC matura-
tion [30]. DCs also have the highest frequency of latent
HSV-1 as compared with the other professional APCs, B
lymphocytes and macrophages [31]. Other viruses, such
as dengue virus [32], cytomegalovirus [33] and Venezue-
lan equine encephalitis virus [34], can also infect DCs and
evoke a variety of influences on antigen processing and
presentation [35].
Although the primary function of DCs is to initiate an
antigen specific immune response, there is evidence that
DCs may in some cases provide a safe haven for certain
viruses. For instance, DCs can support cytomegalovirus
latency and express viral latency associated transcripts
[36]. Reactivation of productive cytomegalovirus replica-
tion can occur in vitro in experimental conditions, which
suggests that cell differentiation pathways act as determi-
nants of reactivation [36]. In addition, HIV can be harbored
on follicular DCs bound on immune complexes [37]. The
virions are resistant to neutralizing antibody in this extra-
cellular setting, and can survive for long periods of time,
creating a state of ‘clinical’ latency.
Conclusion
DCs are being used in experimental systems as potential
therapeutic agents to treat a variety of diseases, and as
targets for vaccine antigen delivery. Although it is difficult
to know at this time whether such methods will have prac-
tical applications, the induction of DCs that contain spe-
cific antigenic peptides in the context of MHC molecules
to elicit a specific T lymphocyte response is very promis-
ing for vaccines and therapeutic strategies. Latouche and
Sadelain [38] generated APCs that express epitopes from
Available online http://respiratory-research.com/content/2/4/245the influenza matrix, along with the necessary appropriate
costimulatory molecules, that can induce antigen specific
cytotoxic T lymphocytes, cytotoxicity and protection.
Recent advances in our understanding of the interaction
between viruses and DC function have largely resulted
from technological breakthroughs in experimental tech-
niques. Continued work on fundamental aspects of the
virus interference with DC function is necessary in order
to develop therapeutic strategies to counteract these
evasive mechanisms. In addition, defining the interaction
of viruses and DCs with the adaptive immune response
will lead to new strategies for developing preventive vac-
cines and improving health.
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